Table 3 The impact of factors other than the RUNX1-RUNX1T1 transcript levels after HSCT on relapse
Factors | 3-year CIR rate (95% CI) | P value |
|---|---|---|
 WBC count at diagnosis | ||
   ≤ 10 × 109/L | 24.6% (9.1–44.0%) | 0.31 |
   > 10 × 109/L | 17.1% (5.1–35.0%) | |
 c-KIT gene | ||
  Mutation | 38.4% (20.0–56.6%) | 0.003 |
  Wild type | 15.4% (2.4–38.9%) | |
 Karyotype | ||
  Sole t(8;21) | 20.6% (4.3–45.4%) | 0.56 |
  Additional abnormalities | 21.6% (7.6–40.3%) | |
 Course acquired to achieve CR | ||
  1 | 19.0% (6.1–372%) | 0.20 |
   > 1 | 24.2% (7.9–45.3%) | |
 Time interval from diagnosis to transplant | ||
   < 8 months | 23.5% (9.4–41.2%) | 0.87 |
   ≥ 8 months | 16.4% (4.3–35.5%) | |
 Disease status pre-HSCT | ||
  1st CR | 18.8% (7.7–33.6%) | 0.071 |
  2nd CR | 33.3% (9.0–60.4%) | |
 Donor resource | ||
  HLA-matched sibling | 31.4% (13.5–51.2%) | 0.039 |
  Alternative donor | 14.6% (4.2–31.0%) | |
 RUNX1-RUNX1T1 transcript levels pre-HSCT | ||
   ≥ 3-log reduction | 11.1% (0.9–36.4%) | <0.0001 |
   < 3-log reduction | 27.9% (14.6–42.9%) | |
 Acute GVHD | ||
  With | 21.6% (7.5–40.5%) | 0.52 |
  Without | 18.9% (6.0–37.3%) | |